17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
27 feb - 
Fredagens aktier: Mærsk trak sløvt C20 i rekord
27 feb - 
Aktier/åbning: Investorerne vender tomlen op for NKT
27 feb - 
Aktier/tendens: NKT til eksamen efter kursridt
Relateret debat
13:52 - 
Jo hurtigere Novo får godkendt Tresiba i USA, jo ..
12:32 - 
Jeg vil overveje at købe Bull Novo X 2 , men jeg forstå..
12:18 - 
Treshiba-godkendelse i US og vi hopper 25-30%. Novo er ..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 feb
NOVO-B
Hej KristofferSR. Hvis du kan vente ligeså længe som puner, er hans råd efter min mening vældig godt..
13
24 feb
NOVO-B
Jeg må indrømme at jeg er vældig glad for at Novo Nordisk har valgt at gå direkte på børsen med NNIT..
9
22 feb
NOVO-B
Hej Kristoffer   Jeg har haft Novo siden 1988 og aldrig solgt en eneste. Mit råd til dig, når du ska..
6
22 feb
NOVO-B
Hej JU! Hvis du har købt aktier i Novo i 2006 og fremefter, tæller du beløbene sammen, dividerer med..
5
07:42
NOVO-B
Nu har jeg været herinde på forum en del år, og i alt den tid jeg kan huske er der folk herinde der ..
4
22 feb
NOVO-B
Du regner gennemsnitskøbsprisen pr aktie ud som du efterfølgende multiplicerer med antalet af solgte..
4
22 feb
NOVO-B
Hvis man kun sælger et antal? Du skriver det selv, sælger det antal du vil og beholder resten. Hvad ..
4
27 feb
NOVO-B
Jeg beholder og supplere ihvert fald mine Novo aktier indtil mine børn bliver voksne, så får de halv..
3
25 feb
NOVO-B
Damn, du er jo et omvandrende leksikon...   Tak for din info...
3
25 feb
NOVO-B
Det er nu meget normalt at placere den sidst i prospektet. Så kan du ikke undgå at se den når du har..
3

FLSmidth: Kobberprisen gjorde comeback i februar

27-02-2015 15:57:04
Kobberprisen har gjort et lille comeback i februar, hvor det for FLSmidth så vigtige metal har klaret sig bedst blandt industrimetallerne noteret på London Meta..

Maersk Drilling/CEO: Raterne er faldet markant

27-02-2015 12:39:21
De fede år er ovre, og nu står den på smalhals i store dele af oliebranchen, både for producenterne og underleverandørerne.Det rammer Maersk Drilling og branche..

Aktier/åbning: Investorerne vender tomlen op for NKT

27-02-2015 09:32:27
Regnskabet fra det danske industriselskab NKT giver anledning til at sende aktien yderligere til vejrs. Sådan lyder dommen fra investorerne fredag morgen, hvor ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske/Nykredit: Tro på renteforhøjelse giver løftet anbefaling
2
Fredagens aktier: Mærsk trak sløvt C20 i rekord
3
Sløvt år for vindmøller i Danmark i 2014
4
USA: BNP overrasker i fjerde kvartal i 2. opgørelse
5
Maersk Drilling/CEO: Når nok 2015-mål selv uden nye kontrakter

Relaterede aktiekurser

Novo Nordisk B A/S 319,70 1,2% Stigning i aktiekurs
Novo-Nordisk A/S 47,75 0,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. februar 2015 14:56:14
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB4 - 2015-02-28 14:56:14 - 2015-02-28 14:56:14 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x